O nei faʻamaumauga na faʻaalia ai Dupixent, pe a faʻaopoopo i le tulaga o le tausiga, faʻaititia tele osofaʻiga a le foma ma, i totonu o le lua vaiaso, faʻavavevave le faʻaleleia o le mama i le faitau aofaʻi o loʻo i ai le eosinophilic phenotype, e pei ona faʻaalia e le maualuga o le toto eosinophils, o se ituaiga o sela paʻepaʻe, ma/po'o fa'atasi ai ma le fa'asili nitric oxide (FeNO), ose fa'ailoga o le ea o le mumū e tele sona sao i le sela.

"O le lolomiina o nei vaega 3 iʻuga mo Dupixent i le New England Journal of Medicine o loʻo faʻamamafaina ai lo latou taua ma aoga aoga aoga mo tamaiti laiti e maua i le fomaʻi maʻi e le pulea lelei," o le tala lea a Leonard B. Bacharier, MD, Polofesa o Pediatrics ma le Faatonu. o le Center for Pediatric Asthma Research, Monroe Carell Jr. Children's Hospital i Vanderbilt University Medical Center i Nashville, Tennessee, ma le tagata suʻesuʻe autu o le faamasinoga. "O nei faʻamaumauga e faʻalauteleina ai lo tatou malamalama i le faʻafefea o le faʻafefeina o le ituaiga 2 fulafula, o se faiga faʻaola e faʻavae i le tele o mataupu o le fomaʻi, e mafai ona faʻaleleia atili faʻamaoniga ma taunuuga mo tamaiti o loʻo mafatia i lenei faʻamaʻi masani masani."

O le Asthma o se tasi lea o fa'ama'i fa'ama'i taatele i tamaiti. E tusa ma le 75,000 tamaiti mai le 6 i le 11 tausaga o loʻo nonofo faʻatasi ma le faʻamaʻi le pulea lelei i le ogaoga i le US, ma le tele o isi lalolagi. E ui lava i togafitiga o lo'o iai nei i le taimi nei o fa'ama'i fa'ama'i ma bronchodilators, o nei tamaiti e ono fa'aauau pea ona o'o i fa'ailoga tuga e pei o le tale, uigi ma faigata ona manava. Latou te ono mana'omia fo'i ni kosi se tele o corticosteroids fa'aletino e mafai ona fa'atupu ai ni fa'alavelave saogalemu.

O taunuʻuga saogalemu mai le faʻataʻitaʻiga e masani lava ona ogatasi ma le faʻamatalaga saogalemu o Dupixent i tagata mamaʻi e 12 tausaga ma matutua atu ma le fomaʻi e le pulea lelei-i-mamala, faʻatasi ai ma le faʻaopoopoga o faʻamaʻi pipisi na lipotia i le 2.2% o maʻi Dupixent ma le 0.7% o gasegase placebo. Ole aofa'iga o fa'alavelave fa'aletonu e 83% mo Dupixent ma le 80% mo placebo. O faʻalavelave faʻalavelave masani na sili atu ona matauina i le Dupixent pe a faʻatusatusa i le placebo o faʻalavelave i luga o tui (18% Dupixent, 13% placebo), faʻamaʻi pipisi o le manava pito i luga (12% Dupixent, 10% placebo) ma eosinophilia (6% Dupixent, 1% placebo).

Dupixent, lea na faia i le fa'aogaina o le VelocImmune® tekinolosi a le Regeneron, ose tino monoclonal antibody e taofia ai le fa'ailogaina o le interleukin-4 (IL-4) ma le interleukin-13 (IL-13) auala ma e le o se immunosuppressant. O le IL-4 ma le IL-13 o ta'avale autu ma totonugalemu o le fulafula ituaiga 2 e tele sona sao i le atopic dermatitis, sela ma le rhinosinusitis masani ma le polyposis nasal (CRSwNP).

O faʻaiʻuga o lenei Vaega 3 faʻataʻitaʻiga na aofia ai foʻi i totonu o le faʻauluina o tulafono faatonutonu a Europa, ma o se faʻaiʻuga mai le European Medicines Agency i tamaiti e maua i le maʻi fomaʻi e faʻamoemoeina i le Q1 2022.

OA MEA E AVEA MAI LENEI TUSI:

The safety results from the trial were generally consistent with the known safety profile of Dupixent in patients aged 12 years and older with uncontrolled moderate-to-severe asthma, with the addition of helminth infections that were reported in 2.
O nei faʻamaumauga na faʻaalia ai Dupixent, pe a faʻaopoopo i le tulaga o le tausiga, faʻaititia tele osofaʻiga a le foma ma, i totonu o le lua vaiaso, faʻavavevave le faʻaleleia o le mama i le faitau aofaʻi o loʻo i ai le eosinophilic phenotype, e pei ona faʻaalia e le maualuga o le toto eosinophils, o se ituaiga o sela paʻepaʻe, ma/po'o fa'atasi ai ma le fa'asili nitric oxide (FeNO), ose fa'ailoga o le ea o le mumū e tele sona sao i le sela.
O faʻaiʻuga o lenei Vaega 3 faʻataʻitaʻiga na aofia ai foʻi i totonu o le faʻauluina o tulafono faatonutonu a Europa, ma o se faʻaiʻuga mai le European Medicines Agency i tamaiti e maua i le maʻi fomaʻi e faʻamoemoeina i le Q1 2022.